A functional genomics screen for microRNA regulators of NF-kappaB signaling
© Olarerin-George et al; licensee BioMed Central Ltd. 2013
Received: 9 August 2012
Accepted: 28 February 2013
Published: 28 February 2013
The nuclear factor-KappaB (NF-κB) pathway is conserved from fruit flies to humans and is a key mediator of inflammatory signaling. Aberrant regulation of NF-κB is associated with several disorders including autoimmune disease, chronic inflammation, and cancer, making the NF-κB pathway an attractive therapeutic target. Many regulatory components of the NF-κB pathway have been identified, including microRNAs (miRNAs). miRNAs are small non-coding RNAs and are common components of signal transduction pathways. Here we present a cell-based functional genomics screen to systematically identify miRNAs that regulate NF-κB signaling.
We screened a library of miRNA mimics using a NF-κB reporter cell line in the presence and absence of tumor necrosis factor (+/- TNF). There were 9 and 15 hits in the -TNF and +TNF screens, respectively. We identified putative functional targets of these hits by integrating computational predictions with NF-κB modulators identified in a previous genome-wide cDNA screen. miR-517a and miR-517c were the top hits, activating the reporter 86- and 126-fold, respectively. Consistent with these results, miR-517a/c induced the expression of endogenous NF-κB targets and promoted the nuclear localization of p65 and the degradation of IκB. We identified TNFAIP3 interacting protein1 (TNIP1) as a target and characterized a functional SNP in the miR-517a/c binding site. Lastly, miR-517a/c induced apoptosis in vitro, which was phenocopied by knockdown of TNIP1.
Our study suggests that miRNAs are common components of NF-κB signaling and miR-517a/c may play an important role in linking NF-κB signaling with cell survival through TNIP1.
KeywordsmicroRNA miRNA miR-517 NF-kappaB TNIP1 TNF RNAi screen apoptosis
Nuclear factor kappa-B (NF-κB) is well conserved, ubiquitously expressed, and a pivotal regulator of immune response, inflammation and cell survival [1–3]. Dysregulation of NF-κB signaling is associated with numerous human diseases ranging from cancer to Crohn's disease , underscoring the role of NF-κB in physiological processes. Since the discovery of NF-κB twenty-six years ago [5, 6], much insight has been gained into the regulation of its signaling and many pathway components have been characterized .
The NF-κB transcription factor is a dimer composed of structurally related Rel family proteins . Of these, the p50-p65 NF-κB heterodimer is best characterized. The cytokine tumor necrosis factor (TNF) is a strong inducer of p50-p65/NF-κB signaling [7, 8]. Upon binding to cell surface receptors, TNF initiates a signaling cascade resulting in the phosphorylation of I-kappaB (IκB) kinase (IKK) -a large cytoplasmic multi-protein complex [7, 9]. IKK in turn phosphorylates IκB-α bound to NF-κB. This results in proteasomal degradation of IκB-α, freeing NF-κB to translocate into the nucleus and activate its targets . Many of these targets include activators (for example, TNF, IL6) and inhibitors (for example, IκB-α, A20, tumor necrosis factor alpha-induced protein 3 interacting protein 1 (TNIP1)) of NF-κB signaling, hence providing context specific feedback regulation.
MicroRNAs (miRNAs) are a class of small non-coding RNAs (ncRNAs) that bind to target mRNAs and promote transcript degradation and/or inhibit translation . Studies suggest that miRNAs are common components of signal transduction pathways, conferring robustness to gene expression and feedback to cellular networks [11–13]. Several miRNAs are known to regulate NF-κB signaling . The earliest example is miR-146, an inhibitor of toll-like receptor (TLR) mediated NF-κB signaling . Another example, the miR-125 family, promotes NF-κB signaling by targeting TNF alpha-induced protein 3 (TNFAIP3), an inhibitor of NF-κB signaling . Further exemplifying the complexity of regulation, miR-21 promotes NF-κB signaling via the PTEN/AKT pathway in MCF-10A cells  but inhibits lipopolysacharride (LPS) mediated NF-κB signaling in TLR4 expressing HEK293 cells . In the above examples, the miRNAs are themselves direct (miR-146, miR-125ab) or indirect (miR-21) targets of NF-κB, suggesting that feedback regulation is common [15, 17, 19].
In this study, we sought to systematically characterize the role of miRNAs in NF-κB signaling using high-throughput cell based screening. We confirmed previously known regulators and identified novel candidates. Further, we derived likely targets for these hits by incorporating other high-throughput/computational datasets. Lastly, we characterized the top hits, miR-517a/c, identified their target, and explored the relationship between their impact on NF-κB signaling and their regulation of apoptosis in the human embryonic kidney cell line HEK293 and the osteosarcoma cell line U-2 OS.
Genome-wide miRNA screen identifies regulators of NF-κB signaling
Top hits in -TNF and +TNF screens.
Putative functional targets of miRNAs derived from overlap of prediction data and genome-wide cDNA screen
High confidence functional targets from miRNA predictions and genome-wide cDNA screen.
miRNAs repressing NF-κB signaling
NM_001172569, NM_002468, NM_001172568, NM_001172567, NM_001172566
NM_021200, NM_001130033, NM_001130035, NM_001130034, NM_001130036
miRNAs activating NF-κB signaling
NM_001099857, NM_001099856, NM_001145255
Secondary screen confirms top hits
Effect of miR-517 family on endogenous NF-κB targets and signaling components
We decided to follow up on the miR-517 family with additional experiments for several reasons: 1) miRNAs typically have a moderate impact on their targets yet miR-517a/c were potent activators of reporter activity in the absence of any added stimulus; 2) we were intrigued that miR-517b did not activate signaling despite extensive sequence similarity to miR-517a/c; and 3) a previous proteomics study by Luo et al. suggested miR-517a involvement in MAPK and TNF signaling in BeWo cells .
Next, we wanted to test the effect of the miR-517 miRNAs on endogenous NF-κB targets. We transfected HEK293 cells with the miR-517 mimics and measured the expression of IL8 and TNF mRNA in unstimulated cells (Figure 4B) and in cells stimulated with TNF for three hours (Figure 4C). In unstimulated cells, miR-517a/c strongly induced IL8 (>160-fold) and TNF (>40-fold) expression while miR-517b had only a modest effect (13- and 4-fold, respectively), confirming the reporter results (Figure 3A). However, in cells treated with TNF, there was no significant change in IL8 and TNF expression in cells transfected with the miR-517 mimics relative to the negative control (Figure 4C). To verify that miR-517a/c were acting through the NF-κB pathway, we co-transfected the mimics with one of two independent small interfering RNAs (siRNAs) against the p65 subunit of NF-κB (efficacy of the siRNAs is demonstrated in Additional file 2, Figure S1). Both siRNAs reduced miR-517a/c induced expression of IL8 and TNF at least 6-fold (Figure 4D; P ≤0.01). Lastly, the nuclear translocation of p65 and the proteasomal degradation of IκB-α are indicative of NF-κB activation. Hence, we evaluated the effect of miR-517a/c on the subcellular localization and expression of p65 and IκB-α in HEK293 cells. miR-517a/c, but not miR-517b, increased nuclear p65 and decreased cytoplasmic IκB-α expression relative to the negative control (Figure 4D). Further, there was increased NF-κB DNA binding activity in the nuclear extracts of cells transfected with miR-517a and miR-517c, but not miR-517b as measured with ELISA (Active Motif TransAM p65 NF-κB assay; Figure 4F). In all, these results confirmed the primary and secondary screen data that miR-517a/c, and not miR-517b, were potent activators of NF-κB signaling.
To confirm that the effects of miR-517a/c on NF-κB signaling were not restricted to HEK293 cells, we also tested primary human umbilical vein endothelial cells (HUVECs). Similarly, miR-517a/c increased target gene expression (IL8, IL6 and TNF) in a p65-dependent manner and increased p65 nuclear translocation (see Additional file 2, Figure S2).
TNIP1 is a direct functional target of miR-517a/c
Next, we took a closer look at the genomic region corresponding to the miR-517a/c binding site in TNIP1. This revealed two interesting features. First, the target site is poorly conserved, with notable differences in the mouse and rat genomes (Figure 5D). Secondly, a SNP (rs72558377) is located in the target site corresponding to the third position of the miRNA seed (Figure 5E). The minor allele (T) results in a G-U wobble base pair, possibly affecting miRNA-target interaction (Figure 5E). To test the functional consequence of this SNP as well as demonstrate direct interaction between miR-517a/c and TNIP1, we cloned sequences containing the major and minor alleles immediately downstream of a firefly luciferase reporter. The same plasmid also expressed Renilla luciferase from a separate constitutive promoter, which was used as a control for transfection efficiency. miR-517a and miR-517c repressed the reporter containing the major allele variant but had no effect on the empty vector (Figure 5F). miR-517b also inhibited reporter activity, but to a lesser extent (Figure 5F). The repression by the miR-517 miRNAs was significantly alleviated in the minor allele reporter (Figure 5F). These results suggested that miR-517a/c interact directly with TNIP1 and that the minor allele of SNP rs72558377 decreases miRNA-target interaction and consequently miR-517a/c mediated repression of TNIP1.
Lastly, given that TNIP1 is a TNF regulated gene  and miRNAs are common in feedback regulation, we hypothesized that NF-κB regulates miR-517a/c which in turn activates the pathway through knockdown of TNIP1. To test this we treated HEK293 cells with TNF over time and measured expression of TNIP1 mRNA and miR-517a/c. While there was a significant increase in TNIP1 expression, miR-517a/c expression was not significantly changed (see Additional file 2, Figure S4).
miR-517a/c induce apoptosis in HEK293 and U-2 OS cells
Next, we tested if miR-517a/c induced apoptosis was a result of TNIP1 knockdown. TNIP1 promotes cell survival and is essential for development. Mice lacking TNIP1 have extensive TNF induced apoptosis in the liver and few are born live . Similar to miR-517a/c, siRNA mediated knockdown of TNIP1 increased cell death in HEK 293 cells (Figure 6D). Also, TNIP1 knockdown increased CASP-3/7 activity (Figure 6E) and cleavage of PARP1 (Figure 6F). Together, these results suggested that knockdown of TNIP1 contributes to the apoptosis inducing activity of miR-517a/c.
Finally, we questioned whether the apoptosis inducing effects of miR-517a/c were specific to cancer-derived/immortalized cell lines. We transfected primary HUVECs with miR-517a/c and, similar to HEK293 and U2-OS cells, we observed increased cell death and CASP-3/7 activity (see Additional file 2, Figure S5). Hence, these results suggest that miR-517a/c can induce apoptosis in primary and immortalized cells.
In this study, we identified 22 miRNAs that regulated basal or TNF-induced NF-κB signaling using high-throughput cell-based screening. Some of these hits are known regulators or direct targets of NF-κB. miR-24, miR-125b and miR-210 are direct NF-κB targets and were hits in our screen [31–33]. Further, miR-125b was recently shown to promote NF-κB signaling by targeting TNFAIP3 . Likewise, miR-210 was recently shown to inhibit signaling by targeting NF-ΚB1/p50 . Both of these findings are consistent with our screening data and suggest miR-125b and miR-210 are feedback regulators of NF-κB signaling. Also, studies by Jiang et al. suggest miR-30e-3p promotes NF-κB signaling by targeting the inhibitor IκB-α . While miR-30e-3p did not meet the cutoff in our +TNF screen (P = 0.05), the related miR-30a-3p was a hit (P = 0.02), activating reporter activity. In all, these results confirmed that our primary screen effectively identified known miRNA regulators of NF-κB signaling.
During the preparation of this study, to our knowledge two other groups published screens investigating the role of miRNAs in NF-κB signaling [36, 37]. A comparison of the experimental methods is detailed in Additional file 1, Table S4. The first by Lu et al. looked at the effects of miRNAs on basal NF-κB reporter activity (that is, non-stimulated) . They found miR-301a was the strongest inducer (approximately 5-fold increase in reporter activity) and that it functioned by targeting NFKB repressing factor (NKRF). miR-301a was not a hit in our screen (P = 0.18; average fold change = 2.3). However, the related family members miR-130a and miR-130b (that is, with the same seed regions as miR-301a and likely overlapping targets) both increased basal reporter activity by 4.5-fold (P = 0.04) and 3.6-fold (P = 0.06), respectively (see Additional file 1, Table S2). Further, miR-130a was a hit in the +TNF screen with a 3.8-fold increase (P = 0.02; Table 1). Hence, our results are in agreement with the Lu et al. study suggesting that the miR-301/miR-130 family positively regulates NF-κB signaling. However, none of the activators confirmed in our secondary screen (miR-483, miR-517a and miR-517c) were hits in the Lu et al. study.
In the second study by Keklikoglou et al., the authors examined the effect of miRNAs on TNF-induced NF-κB reporter activity . They identified 13 miRNA families as hits (P < 0.2). Upon initial evaluation, none of these were hits in our screen. We then relaxed our P-value cutoff from 0.02 to 0.05 and three miRNA families overlapped between the screens: miR-27ab, let-7/miR-98 and miR-500. Interestingly, members of the miR-181 family consistently upregulated the reporter in the Keklikoglou et al. study, while all four members downregulated reporter activity in our study to varying degrees (see Additional file 1, Table S2). Our results are consistent with a recent study by Sun et al. demonstrating miR-181b inhibition of NF-κB through importin-α3 . Further, miR-517a/c were identified as negative regulators in the Keklikoglou screen. miR-517a/c were potent activators in our -TNF screen and were not hits in our +TNF screen (Table 1). However, as noted before, we did observe a slight decrease in reporter activity by miR-517c in the secondary screen (Figure 1C). Interestingly, none of the validated hits from our +TNF secondary screen (miR-210, miR-375 or miR-483) were hits in the Keklikoglou et al. study.
We believe the differences in the screen results largely stem from methodological and technical differences (see Additional file 1, Table S4). All three studies used different NF-κB reporters that were transiently or stably expressed in HEK293/293FT cells. A critical factor may be the sensitivity and specificity of these reporters. Also, the duration of transfection was 72 hours in our screen, but 48 hours in the Lu and Keklikoglou screens. During the optimization of our screen, we found that this longer transfection period was necessary for the optimal impact of our positive controls on reporter activity (data not shown). However, the optimal transfection time depends on several factors including the abundance and half-life of the target proteins as well as the response kinetics of the reporter assay. In all, however, the differences between the screens are not unusual. Such discordance is also found in large RNAi screens [39, 40]. This highlights the importance of replication studies and suggests that follow-up of top hits from all screens is necessary to understand fully the roles of diverse miRNAs in NF-κB signaling.
Determining the mechanism of miRNA action by finding their functional targets is challenging. This problem is two-fold. First, identify the targets, which can number in the hundreds, and second, from these, identify the ones mediating the effect of the miRNA. This can be limited by a lack of preexisting knowledge of the pathway of interest. Also, exhaustively testing the candidates can be unfeasible (miRNA hits times dozens to hundreds of candidates). We addressed this problem by integrating computational predictions from TargetScan and data from our genome-wide cDNA screen for regulators of NF-κB signaling . With this method, we derived high confidence candidate targets for all the miRNAs with the exception of miR-517a/c. This was likely because miR-517a/c had about eight times fewer predicted targets than the other miRNAs (see Additional file 1, Table S3). For future studies, the target list from our analysis has to be validated experimentally. A few high-throughput experimental methodologies for evaluating miRNA targets have been successfully implemented. These include high-throughput sequencing of RNAs isolated by crosslinking immunoprecipitation (HITS-CLIP), photoactivatable-ribonucleoside enhanced crosslinking and immunoprecipitation (PAR-CLIP), ribosome profiling, and microarray analysis of cells or tissues with perturbed miRNA states [41–44]. These datasets are becoming available for more miRNAs and their integration into functional annotation pipelines, such as the one in our study, will be highly informative in identifying functional miRNA-mRNA interactions.
For follow up studies, we focused on the role of primate specific miR-517a and miR-517c as potent inducers of NF-κB signaling. We identified TNIP1, an inhibitor of NF-κB, as a direct target gene. Interestingly, miR-517b was not a hit in our screen despite extensive homology to miR-517a/c (Figure 4A). Also, miR-517b did not phenocopy miR-517a/c in secondary screens (Figure 3A) or knockdown TNIP1 protein expression (Figure 5A). These differences were likely due to a single nucleotide shift in the miR-517b mature sequence relative to miR-517a/c (Figure 4A). According to TargetScan predictions , this shift results in base-pairing between TNIP1 and nucleotides 2 to 7 of miR-517b as opposed to nucleotides 2 to 8 in miR-517a/c-the latter resulting in a more favorable miRNA-target interaction. This result highlights the importance of the miRNA seed in mediating miRNA-target interactions and suggests caution in extrapolating the function of individual miRNAs to their family members, particularly when their seed regions differ. Interestingly, during the preparation of this study we examined sequence reads of the miR-517b locus from miRBase , the central repository for miRNA sequences, and found a variant identical to miR-517a. This suggests that the shifted variant is either a result of read errors or a true 5' isomiR-the likes of which have been demonstrated in multiple species . We informed the curators of miRBase, and the unshifted sequence (identical to miR-517a) is the new reference for miR-517b (now miR-517b-3p) as of miRBase v17.
While knockdown of TNIP1 was sufficient to induce expression of TNF and IL8 as much as 18- and 56-fold, respectively (Figure 5B), miR-517a/c were more potent inducers (Figure 4B). Also, overexpression of TNIP1 did not completely block miR-517a/c induced expression of TNF and IL8. This suggests that the effect of miR-517a/c on NF-κB signaling may be mediated by other genes in the pathway in addition to TNIP1. This is consistent with numerous studies suggesting that miRNAs regulate cellular pathways by targeting multiple components . Further studies are needed to elucidate additional miR-517a/c targets. The TNIP1 3'UTR harbors a functional SNP in the miR-517a/c binding site. SNPs are the most common form of human polymorphisms with millions validated in the National Center for Biotechnology Information (NCBI)'s dbSNP. Here, we show that the minor allele of SNP rs72558377 (T) creates a G-U base pair between miR-517a/c and TNIP1 that disrupts binding, resulting in reduced knockdown of TNIP1. This is consistent with studies demonstrating the deleterious effect of G-U base pairing between a miRNA's seed and target mRNA [49, 50]. There are currently no reported phenotypes associated with rs72558377, but future studies may shed light on the potential consequence of this SNP and the broader biological function of miR-517a/c.
An oncogenic role for miR-517a has been suggested in liver and brain tumors [28, 29]. Given miR-517a/c activated NF-κB signaling in our screen, this is consistent with the well-established anti-apoptotic role of NF-κB [51, 52]. However, we found miR-517a/c induced apoptosis in the immortalized cell line HEK293, in the osteosarcoma cell line U-2 OS and in primary HUVECs. Corroborating our results, a study by Yoshitomi et al. found miR-517a induced apoptosis in the bladder cancer cell lines T24 and BOY . Also, interestingly, Na et al. recently found miR-517a down-regulated in the placenta of patients with complete hydatidiform moles-a condition characterized by increased trophoblast proliferation . Hence, our results suggest that the knockdown of TNIP1 by miR-517a/c may both activate NF-κB signaling and repress its anti-apoptotic activity. Also, these conflicting functions of miR-517a/c may reflect the complex role of NF-κB in the regulation of cell survival. In some cases, NF-κB can promote apoptosis in a context and cell type-specific manner . Additional studies are needed to understand how survival signals differ in various cell types in response to miR-517a/c and the role NF-κB may play in this process. As miR-517a/c are suppressed in most cell/tissue types, their reported activation by demethylating drugs, such as 5-aza-2′-deoxycytidine (5-aza-dc)  may have therapeutic value in the treatment of certain cancers.
This study provides a valuable resource for the functional annotation of miRNAs in the NF-κB pathway. Our data suggest that miRNAs are common regulators. While additional studies are needed to identify the functional targets of these miRNAs, we provide a starting list of likely candidates by integrating target predictions and cDNA screening data. Lastly, we conclude that miR-517a/c are pro-apoptotic and potent activators of NF-κB that function at least in part through TNIP1.
Tissue culture and cell maintenance
HEK293 andU-2 OS cells were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). Primary HUVEC cells (Lonza, Walkersville, MD, USA) were a kind gift from Dr. Vladimir Muzykantov (University of Pennsylvania) and were used no later than passage 6. The NF-κB-luc (HEK293) cell line was a generous gift from Dr. Sumit Chanda (Burnham Institute). Briefly, HEK293 cells were transfected with 2 μg of a 5X NF-κB-luc luciferase reporter in a 100 mm dish and clonal selection was carried out with neomycin. HEK293 and U-2 OS cells were maintained in growth media containing 10% fetal bovine serum (FBS), 1X penicillin/streptomycin/glutamine (Life Technologies, Grand Island, NY, USA) in (D)MEM. HUVECs were maintained in growth media made with the EGM-2 BulletKit (Lonza; CC-3162) according to the manufacturer's protocol. All cells were kept in a humidified incubator at 37°C and 5% CO2.
siRNAs and miRNA
All Ambion miRNA mimics used in the primary screen and follow-up studies as well as siRNAs against p65 (#216912 and #143124) were from Life Technologies. siRNAs against TNIP1 (SI04315815 and SI04317341) were from Qiagen (Valencia, CA, USA).
A miRNA mimic library (Ambion; Pre-miR library v 8.0) was spotted at 1.6 pmol/well in a 384-well format. NF-κB-luc cells were reverse transfected with Lipofectamine2000 (Life Technologies). Briefly, 10 μL of OptiMEM (Life Technologies) was added to each spotted well. A total of 10 μL of transfection reagent mix containing 1% Lipofectamine2000 in OptiMEM was then added to each well and incubated for 20 minutes. Cells were prepared in 2X growth media ((D)MEM, 20% FBS, 2X L-glutamine (Life Technologies)) at a final concentration of 1.5 × 105 cells/mL. A total of 20 μL of cell suspension was added to each well. Plates were maintained under normal growth conditions for 72 hours. Stock TNF (Sigma, St. Louis, MO, USA) solution was diluted in (D)MEM and 5 uL was added to each well to a final concentration of 40 ng/mL. Luciferase levels were quantified 8.5 hours later, using BriteLite assay systems (Perkin Elmer, Shelton, CT, USA) on an Envision Multilabel plate reader (Perkin Elmer) following the manufacturer's protocols. Raw luminescence values were log transformed and robust Z-scores were calculated for each well using the following formula: Z-score = (xi -med(x))/mad(x). Where xi is the luminescence value for well i, med(x) is the median of the plate and mad(x) is the median absolute deviation of the plate. P-values were estimated with a Wilcoxon rank sum test (two-sided) comparing each duplicate pair to the experiment wide distribution.
Secondary screen was performed as per the primary screen in a 96-well format (final volume 100 μL). NF-κB-luc cells were co-transfected with the miRNA mimics (50 nM final) and pGL4.74 Renilla construct (Promega, San Luis Obispo, CA, USA; final 30 ng/well). Following treatment with TNF (40 ng/mL-final), firefly and Renilla luciferase levels were quantified using the Dual-Glo Luciferase Assay System (Promega) according to the manufacturer's protocol.
HEK293 and HUVEC cells were plated in a 96-well plate at 5,000 cells/well in 100 μL of the respective growth media with no antibiotics. The next day, cells were transfected with miRNA mimics at a final concentration of 50 nM with Lipofectamine RNAiMAX (Life Technologies) according to the manufacturer's protocol. Caspase activity was measured 96 hours later with the Caspase-Glo 3/7 Assay (Promega) according to the manufacturer's protocol.
Computational analysis for high-confidence miRNA targets
miRNA targets were predicted using Perl scripts from TargetScanHuman (http://www.Targetscan.org) version 6.0 as per the websites instructions [21, 22]. Predictions were made irrespective of target site or miRNA conservation. The 328 miRNA sequences used as input for the program are listed in Additional file 1, Table 1 and correspond to the miRBase v 8.0 annotation used in the construction of the library. For the cross-screen comparisons, the list of modulators was derived from a previously described study . All subsequent analyses were done in R.
Transfection and TNF stimulation of HEK293, U-2 OS and HUVEC cells
HEK293 and U-2 OS cells were seeded in 6-well (for protein) or 24-well (for RNA) plates at 1 × 105 and 2.5 × 104 cells/well, respectively, in media containing 10% FBS and 1X L-glutamine in OptiMEM/(D)MEM (1:1). HUVEC cells were seeded in 60 mm dishes (for protein) or 24-well plates (for RNA) at 1.6 × 105 and 4 × 104 cells/well respectively, in HUVEC growth medium without antibiotics. Cells were co-transfected the next day with plasmids and miRNAs using Lipofectamine 2000 (Life Technologies) according to the manufacturer's protocol. RNAiMAX was used for all other transfections according to the manufacturer's protocol. miRNAs and siRNAs were transfected at a final concentration of 50 nM each. Plasmids were transfected at a final concentration of 125 ng/well (24-well plate) or 500 ng/well (6-well plate). Mimic 'miR-517a/c' contained equal amounts of miR-517a and miR-517c. The amount of nucleic acid was held constant across conditions in every experiment by adding the respective negative controls (negative control siRNAs/mimics or empty vector). Cells were transfected for 72 hours (unless otherwise stated in the text) and maintained under normal growth conditions before harvesting for protein or RNA. HEK293 cells were stimulated with TNF at a final concentration of 40 ng/mL for 3 hours (unless otherwise indicated) before processing for RNA.
Whole cell protein extracts were isolated from HEK293 cells with ice-cold RIPA buffer. Nuclear and cytoplasmic extracts were isolated with the NE-PER Nuclear and Cytoplasmic Extraction kit (Pierce, Rockford, IL, USA). All extraction buffers were supplemented with a protease inhibitor cocktail (Complete; Roche, Indianapolis, IN, USA). Protein concentrations were quantified with the DC protein assay (BioRad, Hercules, CA, USA). A total of 50μg (whole cell) or 10μg (nuclear/cytoplasmic extracts) of protein was resolved on Tris-HCL SDS gels (BioRad) and transferred to polyvinylidene difluoride (PVDF) membranes. Membranes were blocked for 1 hour at room temperature in blocking solution (2.5% milk, 0.5% Tween20, 1X Tris-buffered saline) followed by a 1 hour incubation with the primary antibody in blocking solution. Primary antibodies used were: anti-p65 (4764S), anti-IκB-α (4814S), anti-Lamin A/C (2032), anti-PARP (9532S), anti-HSP-90 (4875; Cell Signaling Technologies, Danvers, MA, USA), anti-Tubulin (ab7291; Abcam, Cambridge, MA, USA), anti-TNIP1 (15104-1-AP; Proteintech Group, Chicago, IL, USA) and anti-GAPDH (sc-25778; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Membranes were rinsed twice each with TBS-0.1% tween and blocking solution then probed with anti-rabbit immunoglobulin G (IgG) horseradish peroxidase (HRP)-linked secondary antibody (NA934-1ML; GE Healthcare, Mickleton, NJ, USA) for 30 minutes in blocking solution. Membranes were rinsed 4 times for 15 minutes in TBS-0.1% tween solution followed by the application of enhanced chemiluminescence (ECL) western blotting detection reagent (GE Healthcare) and developed by standard autoradiograph techniques.
p65 ELISA assay
p65 activation was measured in nuclear extracts of HEK293 cells with a commercial DNA binding ELISA kit (ActiveMotif (Carlsbad, CA, USA) TransAM NFκB p65 Chemi) according to the manufacturer's protocol. A total of 500 ng of protein was used for each assay.
Cloning of TNIP1 construct
Human full-length TNIP1 cDNA (BC012133; Thermo Scientific, Waltham, MA, USA) was PCR amplified with primer set 5'-GCATACTAGTAAGCTCCCCGTCCTCGGCCA-3' and 5'- GCATCTCGAGAGCCTCTCATCCAGCTGAGGCTCT-3' (Integrated DNA Technologies, Coralville, IA, USA) and cloned into the SpeI and XhoI restriction sites of pCMV-sport6 vector (Invitrogen) using standard recombinant DNA techniques. The resulting construct was verified by DNA sequencing. Expression of TNIP1 from the construct was confirmed by western blot.
Cloning of 3'UTR reporter constructs
Both strands of the respective target regions were synthesized (Intergrated DNA Technologies) with overhangs for ligation into the NheI and XhoI restriction sites of the pmiRGlo Dual Luciferase vector (Promega). Complementary strands were annealed by mixing 50 μL of each 100 μM oligo (in 1x Tris-EDTA (TE)) with 100 μL of 2X annealing buffer (100 mM NaCl in 1X TE) and placing in a 99°C water bath for 2 minutes. The heat source was then turned off and the samples were allowed to cool to room temperature. Annealed oligos were then purified with the Qiaquick Nucleotide removal kit (Qiagen). The resulting double stranded approximately 46 bp DNA segment was diluted (1:100) and cloned into the restriction sites of the pmiRGlo vector using standard recombinant DNA techniques. The resulting constructs were verified by DNA sequencing. The oligos synthesized were as follows: TNIP1 major allele sense and antisense (5'-CTAGATCCCTGGATAGCTATTTGCACGAATCATGGACATAAATCCA-3', 5'- TCGATGGATTTATGTCCATGATTCGTGCAAATAGCTATCCAGGGAT-3'), TNIP1 minor allele sense and antisense (5'-CTAGATCCCTGGATAGCTATTTGCATGAATCATGGACATAAATCCA-3', 5'- TCGATGGATTTATGTCCATGATTCATGCAAATAGCTATCCAGGGAT-3').
RNA extraction and quantitative PCR
RNA was extracted from HEK293 cells in high-throughput format with the Nucleospin 96 RNA kit (Macherey-Nagel, Bethlehem, PA, USA) following the manufacturer's protocol. For the TNF time-course experiment, RNA was extracted with miRNeasy kit (Qiagen) following the manufacturer's suggested protocol for total RNA isolation (including small RNAs). cDNA was generated from 500 ng of RNA using the miScript Reverse Transcription kit (Qiagen) and quantitative PCR was performed on the 7900HT Real-Time PCR System (Life Technologies) using the Quantitect SYBR Green PCR kit (Qiagen) according to the manufacturers' protocols. The ΔΔCT method was used for relative expression quantification using the RQ manager software v2.4 (Life Technologies). 18S rRNA (or RNU6B) was the endogenous reference for all mRNA (or miRNA) quantification experiments. All primer sets were purchased from Qiagen: TNF (QT01079561), IL8 (QT00000322), IL6 (QT00083720), TNIP1(QT00044072), 18S rRNA(QT00199367), miR-517a (MS00004459), miR-517c (MS00009954), RNU6B (MS00029204).
All comparisons between group means were performed with a two-sided heteroscedastic Student's t-test.
(Dulbecco's) modified Eagle's medium
enzyme-linked immunosorbent assay
fetal bovine serum
human umbilical vein endothelial cells
I kappa-B kinase
median absolute deviations
nuclear factor kappa-B
nuclear factor kappa-B responsive luciferase
nuclear factor kappa-B repressing factor
poly(ADP-ribose) polymerase 1
polymerase chain reaction
small interfering RNAs
single nucleotide polymorphism
tumor necrosis factor
tumor necrosis factor alpha-induced protein 3 interacting protein
We thank members of the Hogenesch lab for comments on this manuscript. Also, we thank Dr. Sumit Chanda for the NF-κB reporter cell line and Dr. Vladimir Muzykantov for the HUVECs. JBH is supported by the National Institutes of Health grants 2-R01-NS054794-06 and 5-R01-HL097800-04 and by DARPA (BAA-11-65) (to John Harer, Duke University); AO is supported by the National Human Genome Research Institute training grant T32HG000046. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Human Genome Research Institute or the National Institutes of Health.
- Hayden MS, West AP, Ghosh S: NF-kappaB and the immune response. Oncogene. 2006, 25: 6758-6780. 10.1038/sj.onc.1209943.View ArticlePubMed
- Gerondakis S, Grumont R, Gugasyan R, Wong L, Isomura I, Ho W, Banerjee A: Unravelling the complexities of the NF-κB signalling pathway using mouse knockout and transgenic models. Oncogene. 2006, 25: 6781-6799. 10.1038/sj.onc.1209944.View ArticlePubMed
- May M: Rel/NF-κB and IκB proteins: an overview. Semin Cancer Biol. 1997, 8: 63-73. 10.1006/scbi.1997.0057.View ArticlePubMed
- Courtois G, Gilmore TD: Mutations in the NF-κB signaling pathway: implications for human disease. Oncogene. 2006, 25: 6831-6843. 10.1038/sj.onc.1209939.View ArticlePubMed
- Sen R, Baltimore D: Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell. 1986, 46: 705-716. 10.1016/0092-8674(86)90346-6.View ArticlePubMed
- Sen R, Baltimore D: Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell. 1986, 47: 921-928. 10.1016/0092-8674(86)90807-X.View ArticlePubMed
- Gilmore TD: Introduction to NF-κB: players, pathways, perspectives. Oncogene. 2006, 25: 6680-6684. 10.1038/sj.onc.1209954.View ArticlePubMed
- Locksley RM, Killeen N, Lenardo MJ: The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001, 104: 487-501. 10.1016/S0092-8674(01)00237-9.View ArticlePubMed
- Scheidereit C: IκB kinase complexes: gateways to NF-κB activation and transcription. Oncogene. 2006, 25: 6685-6705. 10.1038/sj.onc.1209934.View ArticlePubMed
- Sun W, Julie Li YS, Huang HD, Shyy JY, Chien S: microRNA: a master regulator of cellular processes for bioengineering systems. Annu Rev Biomed Eng. 2010, 12: 1-27. 10.1146/annurev-bioeng-070909-105314.View ArticlePubMed
- Inui M, Martello G, Piccolo S: MicroRNA control of signal transduction. Nat Rev Mol Cell Biol. 2010, 11: 264-275.View Article
- Stark A, Brennecke J, Bushati N, Russell RB, Cohen SM: Animal microRNAs confer robustness to gene expression and have a significant impact on 3′UTR evolution. Cell. 2005, 123: 1133-1146. 10.1016/j.cell.2005.11.023.View ArticlePubMed
- Tsang J, Zhu J, Van Oudenaarden A: MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals. Mol Cell. 2007, 26: 753-767. 10.1016/j.molcel.2007.05.018.PubMed CentralView ArticlePubMed
- Ma X, Becker Buscaglia LE, Barker JR, Li Y: MicroRNAs in NF-B signaling. J Mol Cell Biol. 2011, 3: 159-166. 10.1093/jmcb/mjr007.PubMed CentralView ArticlePubMed
- Taganov KD: NF- B-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA. 2006, 103: 12481-12486. 10.1073/pnas.0605298103.PubMed CentralView ArticlePubMed
- Kim SW, Ramasamy K, Bouamar H, Lin AP, Jiang D, Aguiar RCT: MicroRNAs miR-125a and miR-125b constitutively activate the NF-κB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl Acad Sci USA. 2012, 109: 7865-7870. 10.1073/pnas.1200081109.PubMed CentralView ArticlePubMed
- Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K: STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell. 2010, 39: 493-506. 10.1016/j.molcel.2010.07.023.PubMed CentralView ArticlePubMed
- Sheedy FJ, Palsson-McDermott E, Hennessy EJ, Martin C, O'Leary JJ, Ruan Q, Johnson DS, Chen Y, O'Neill LAJ: Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol. 2009, 11: 141-147.View ArticlePubMed
- Zhou R, Hu G, Liu J, Gong AY, Drescher KM, Chen XM: NF-kappaB p65-dependent transactivation of miRNA genes following cryptosporidium parvum infection stimulates epithelial cell immune responses. PLoS Pathogens. 2009, 5: e1000681-10.1371/journal.ppat.1000681.PubMed CentralView ArticlePubMed
- Halsey TA, Yang L, Walker JR, Hogenesch JB, Thomas RS: A functional map of NFκB signaling identifies novel modulators and multiple system controls. Genome Biol. 2007, 8: R104-10.1186/gb-2007-8-6-r104.PubMed CentralView ArticlePubMed
- Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP: MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell. 2007, 27: 91-105. 10.1016/j.molcel.2007.06.017.PubMed CentralView ArticlePubMed
- Garcia DM, Baek D, Shin C, Bell GW, Grimson A, Bartel DP: Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs. Nat Struct Mol Biol. 2011, 18: 1139-1146. 10.1038/nsmb.2115.PubMed CentralView ArticlePubMed
- Luo SS, Ishibashi O, Ishikawa G, Ishikawa T, Katayama A, Mishima T, Takizawa T, Shigihara T, Goto T, Izumi A, Ohkuchi A, Matsubara S, Takeshita T, Takizawa T: Human villous trophoblasts express and secrete placenta-specific microRNAs into maternal circulation via exosomes. Biol Reprod. 2009, 81: 717-729. 10.1095/biolreprod.108.075481.View ArticlePubMed
- Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, Barzilai A, Einat P, Einav U, Meiri E, Sharon E, Spector Y, Bentwich Z: Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet. 2005, 37: 766-770. 10.1038/ng1590.View ArticlePubMed
- Heyninck K: The zinc finger protein A20 inhibits TNF-induced NF-kappa B-dependent gene expression by interfering with an RIP- or TRAF2-mediated transactivation signal and directly binds to a novel NF-kappa B-inhibiting protein ABIN. J Cell Biol. 1999, 145: 1471-1482. 10.1083/jcb.145.7.1471.PubMed CentralView ArticlePubMed
- Mauro C: ABIN-1 binds to NEMO/IKK and co-operates with A20 in inhibiting NF-B. J Biol Chem. 2006, 281: 18482-18488. 10.1074/jbc.M601502200.View ArticlePubMed
- Tian B, Nowak DE, Jamaluddin M, Wang S, Brasier AR: Identification of direct genomic targets downstream of the nuclear factor-kappaB transcription factor mediating tumor necrosis factor signaling. J Biol Chem. 2005, 280: 17435-17448. 10.1074/jbc.M500437200.View ArticlePubMed
- Li M, Lee KF, Lu Y, Clarke I, Shih D, Eberhart C, Collins VP, Van Meter T, Picard D, Zhou L, Boutros PC, Modena P, Liang ML, Scherer SW, Bouffet E, Rutka JT, Pomeroy SL, Lau CC, Taylor MD, Gajjar A, Dirks PB, Hawkins CE, Huang A: Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell. 2009, 16: 533-546. 10.1016/j.ccr.2009.10.025.PubMed CentralView ArticlePubMed
- Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Minguez B, Savic R, Ward SC, Thung S, Chiang DY, Alsinet C, Tovar V, Roayaie S, Schwartz M, Bruix J, Waxman S, Friedman SL, Golub T, Mazzaferro V, Llovet JM: MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology. 2011, 140: 1618-1628. 10.1053/j.gastro.2011.02.009. e16PubMed CentralView ArticlePubMed
- Oshima S, Turer EE, Callahan JA, Chai S, Advincula R, Barrera J, Shifrin N, Lee B, Yen B, Woo T, Malynn BA, Ma A: ABIN-1 is a ubiquitin sensor that restricts cell death and sustains embryonic development. Nature. 2008, 457: 906-909.PubMed CentralView ArticlePubMed
- Zhou R, Hu G, Gong AY, Chen XM: Binding of NF-kappaB p65 subunit to the promoter elements is involved in LPS-induced transactivation of miRNA genes in human biliary epithelial cells. Nucleic Acids Res. 2010, 38: 3222-3232. 10.1093/nar/gkq056.PubMed CentralView ArticlePubMed
- Tili E, Michaille JJ, Cimino A, Costinean S, Dumitru CD, Adair B, Fabbri M, Alder H, Liu CG, Calin GA, Croce CM: Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol. 2007, 179: 5082-5089.View ArticlePubMed
- Zhang Y, Fei M, Xue G, Zhou Q, Jia Y, Li L, Xin H, Sun S: Elevated levels of hypoxia-inducible microRNA-210 in pre-eclampsia: new insights into molecular mechanisms for the disease. J Cell Mol Med. 2012, 16: 249-259. 10.1111/j.1582-4934.2011.01291.x.PubMed CentralView ArticlePubMed
- Qi J, Qiao Y, Wang P, Li S, Zhao W, Gao C: microRNA-210 negatively regulates LPS-induced production of proinflammatory cytokines by targeting NF-κB1 in murine macrophages. FEBS Lett. 2012, 586: 1201-1207. 10.1016/j.febslet.2012.03.011.View ArticlePubMed
- Jiang L, Lin C, Song L, Wu J, Chen B, Ying Z, Fang L, Yan X, He M, Li J, Li M: MicroRNA-30e* promotes human glioma cell invasiveness in an orthotopic xenotransplantation model by disrupting the NF-κB/IκBα negative feedback loop. J Clin Invest. 2012, 122: 33-47. 10.1172/JCI58849.PubMed CentralView ArticlePubMed
- Lu Z, Li Y, Takwi A, Li B, Zhang J, Conklin DJ, Young KH, Martin R, Li Y: miR-301a as an NF-κB activator in pancreatic cancer cells. EMBO J. 2010, 30: 57-67.PubMed CentralView ArticlePubMed
- Keklikoglou I, Koerner C, Schmidt C, Zhang JD, Heckmann D, Shavinskaya A, Allgayer H, Gückel B, Fehm T, Schneeweiss A, Sahin O, Wiemann S, Tschulena U: MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways. Oncogene. 2012, 31: 4150-4163. 10.1038/onc.2011.571.View ArticlePubMed
- Sun X, Icli B, Wara AK, Belkin N, He S, Kobzik L, Hunninghake GM, Vera MP, Blackwell TS, Baron RM, Feinberg MW: MicroRNA-181b regulates NF-κB-mediated vascular inflammation. J Clin Invest. 2012, 122: 1973-1990.PubMed CentralPubMed
- Cherry S: What have RNAi screens taught us about viral-host interactions?. Curr Opin Microbiol. 2009, 12: 446-452. 10.1016/j.mib.2009.06.002.PubMed CentralView ArticlePubMed
- Mohr S, Bakal C, Perrimon N: Genomic screening with RNAi: results and challenges. Annu Rev Biochem. 2010, 79: 37-64. 10.1146/annurev-biochem-060408-092949.PubMed CentralView ArticlePubMed
- Chi SW, Zang JB, Mele A, Darnell RB: Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature. 2009, 460: 479-486.PubMed CentralPubMed
- Hafner M, Landthaler M, Burger L, Khorshid M, Hausser J, Berninger P, Rothballer A, Ascano M, Jungkamp AC, Munschauer M, Ulrich A, Wardle GS, Dewell S, Zavolan M, Tuschl T: Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell. 2010, 141: 129-141. 10.1016/j.cell.2010.03.009.PubMed CentralView ArticlePubMed
- Guo H, Ingolia NT, Weissman JS, Bartel DP: Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010, 466: 835-840. 10.1038/nature09267.PubMed CentralView ArticlePubMed
- Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005, 433: 769-773. 10.1038/nature03315.View ArticlePubMed
- Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005, 120: 15-20. 10.1016/j.cell.2004.12.035.View ArticlePubMed
- Kozomara A, Griffiths-Jones S: miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 2010, 39: D152-D157.PubMed CentralView ArticlePubMed
- Ryan BM, Robles AI, Harris CC: Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer. 2010, 10: 389-402. 10.1038/nrc2867.PubMed CentralView ArticlePubMed
- Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004, 116: 281-297. 10.1016/S0092-8674(04)00045-5.View ArticlePubMed
- Doench JG, Sharp PA: Specificity of microRNA target selection in translational repression. Genes Dev. 2004, 18: 504-511. 10.1101/gad.1184404.PubMed CentralView ArticlePubMed
- Brennecke J, Stark A, Russell RB, Cohen SM: Principles of microRNA-target recognition. PLoS Biol. 2005, 3: e85-10.1371/journal.pbio.0030085.PubMed CentralView ArticlePubMed
- Wang CY, Mayo MW, Baldwin AS: TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science. 1996, 274: 784-787. 10.1126/science.274.5288.784.View ArticlePubMed
- Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM: Suppression of TNF-alpha-induced apoptosis by NF-kappa B. Science. 1996, 274: 787-789. 10.1126/science.274.5288.787.View ArticlePubMed
- Yoshitomi T, Kawakami K, Enokida H, Chiyomaru T, Kagara I, Tatarano S, Yoshino H, Arimura H, Nishiyama K, Seki N, Nakagawa M: Restoration of miR-517a expression induces cell apoptosis in bladder cancer cell lines. Oncol Rep. 2011, 25: 1661-1668.PubMed
- Na Q, Wang D, Song W: Underexpression of 4 placenta-associated microRNAs in complete hydatidiform moles. Int J Gynecol Cancer. 2012, 22: 1075-1080. 10.1097/IGC.0b013e3182574439.View ArticlePubMed
- Kucharczak J, Simmons MJ, Fan Y, Gélinas C: To be, or not to be: NF-κB is the answer-role of Rel/NF-κB in the regulation of apoptosis. Oncogene. 2003, 22: 8961-8982. 10.1038/sj.onc.1207230.View ArticlePubMed
- Tsai KW, Kao HW, Chen HC, Chen SJ, Lin W: Epigenetic control of the expression of a primate-specific microRNA cluster in human cancer cells. Epigenetics. 2009, 4: 587-592. 10.4161/epi.4.8.10230.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.